It was recently estimated that 75% of sessile serrated adenomas with methylate MLH1 are MSI, and progress to mutant BRAF MSI cancers; however, about 25% do not silence the MLH1 gene and become BRAF mutant MSS cancers [178]. This evidence concerns the gene BRAF and cancer.